GOLD Revaluation

Gold is trading at all-time highs, around $2,950 per ounce. Several catalyst may be at play driving the price higher. The revalue of gold reserves to higher prices, was mentioned by new Treasury Secretary Scott Bessent. The US is said to hold 8,133 metric tons of gold, but an audit would be necessary to verify the accuracy. Weekly chart of gold below. Thank you for reading.

Axsome Fourth Quarter Financial Results

Axsome released 4th quarter financial results today, a couple of highlights from the quarterly and year end release. 

• ADHD phase 3 results, first quarter of 2025
• AXS-05 for Alz Agitation NDA to be submitted 2nd half 2025
• AXS-12 for Narcolepsy NDA to be submitted 2nd half 2025
• $315 million in cash, end of 2024

Good quarter, and great 2024 completed. The stock is at an all-time high level around $130.00 per share chart below. Thank you for reading. 

 

Symbravo Receives FDA Approval for Acute Migraine

Axsome Therapeutics has received FDA approval for migraine drug AXS-07, or known commercially now as Symbravo. The drug's patent extends out to 2040, so there will be plenty years of runway for commercialization. The list of approved drugs that address unmet medical needs now extends to three, which include Auvelity, Sunosi, and now Symbravo. The company is operating at a very high level, of advancing through clinical trials to FDA approval. Click on chart below, as Axsome stock has closed at an all-time high price. Thank you for reading. 

MM120 for Generalized Anxiety Disorder

MindMed (MNMD) is a psychedelic company addressing unmet medical need GAD (Generalized Anxiety Disorder) with lead drug MM120. The companies website is here MindMed. Some quick facts regarding MindMed. 

• 540 Million Market Cap
• 80M Shares outstanding
• 295 Million cash
• MM120 Breakthrough Therapy Designation
• MM120 Patent to 2041
• MM120 in Phase 3 for GAD
• Share Price $7.20

The company has successfully completed a phase 2b for GAD, and received Breakthrough Therapy Designation for MM120 afterwards. The company is now in phase 3 for GAD. They will be using the HAM-A assessment at 12 weeks, after a single dose of MM120. Here is where you can find the company's medical Presntations. The goal of MindMed is to have two phase 3 clinical trials and a 40 week long-term extension study all completed by the end of 2026. Their past and current clinical trails MM-120 Clinical Trials. Thank you for reading.